Olympus Corporation
【Olympus】Completion of BioProtect Subsidiary Acquisition ｜ June 2026
Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing its full subsidiary status. The acquisition price was approximately 43.3 billion yen, and its impact on future performance is being examined.
Key Figures
- Acquisition Price: Approx. 43.3 billion yen
- Number of Shares Acquired: 16,925,621 shares
- Ownership Ratio: 100%
AI要約
Overview of the Acquisition
Olympus has acquired all shares of Israel-based medical device manufacturer BioProtect Ltd., completing its full subsidiary status. BioProtect is engaged in research, development, and manufacturing of biodegradable prostate cancer balloons and rectal spacers, with an acquisition cost of approximately 43.3 billion yen. The acquisition aims to strengthen Olympus's medical business and expand globally. The impact on upcoming performance is under examination.
Future Outlook and Corporate Strategy
The specific impact on performance following the acquisition remains undecided, but Olympus aims to develop advanced medical devices and expand its market through this subsidiary acquisition. Detailed earnings guidance and business strategies will be disclosed separately. This project is being closely watched by investors as part of the company's growth strategy in the medical field.
Olympus Corporation
Company overview · Stock price · Financial data · All IR
